Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 17 for:    triplet | Huntington Disease
Previous Study | Return to List | Next Study

Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease (ADORE-DH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03252535
Recruitment Status : Active, not recruiting
First Posted : August 17, 2017
Last Update Posted : December 13, 2019
Sponsor:
Collaborator:
Cellavita Pesquisa Científica Ltda
Information provided by (Responsible Party):
Azidus Brasil

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : April 2022
Publications: